Company Profile

Immune-Onc Therapeutics Inc
Profile last edited on: 5/2/2023      CAGE: 874Y0      UEI: W7Z2EM93HXN8

Business Identifier: Discovery and development of novel myeloid checkpoint inhibitors for cancer patients
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

795 San Antonio Road
Palo Alto, CA 94303
   (917) 569-5522
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

Developing therapeutic antibodies for cancer treatment, Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company structured around discovery and development of novel myeloid checkpoint inhibitors. Describing themselves as "charting a new course in Immunotherapy", Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitorsManagement's indicated objective is to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that would/will disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Charlene Liao -- Founder, President and CEO

  Luke Chung -- Executive Medical Director & Global Projects Lead, Clinical Development

  Kyu Hee Hong -- Director of Bioanalysis

  Ji Li -- Chief of Staff

  Guo Liang Yu -- Co-founder and CEO

  Krista Mccutcheon -- Director of Antibody Engineering

  An Song -- Chief Scientific Officer

  Christopher Whitmore -- Chief Financial Officer

  Paul Woodard -- Chief Medical Officer

  Ying Zhu -- Vice President, CMC Development

Company News

There are no news available.